Cisen Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,212	1,161	983.39	997.95	938.98
Short-Term Investments	461.47	357.58	154.11	236.27	-
Trading Asset Securities	1,730	1,275	1,638	1,550	1,485
Cash & Short-Term Investments	3,403	2,794	2,775	2,784	2,424
Cash Growth	21.83%	0.66%	-0.32%	14.87%	-4.46%
Accounts Receivable	1,041	1,257	1,363	1,272	1,048
Other Receivables	0.84	0.75	4.24	9.25	11.35
Receivables	1,042	1,257	1,367	1,281	1,060
Inventory	623.69	810.43	708.22	580.43	594.65
Other Current Assets	140.94	100.34	119.41	99.63	66.45
Total Current Assets	5,210	4,962	4,970	4,745	4,145
Property, Plant & Equipment	1,675	1,546	1,390	1,489	1,591
Long-Term Investments	390.03	665.08	602.27	265.08	308.01
Other Intangible Assets	196.29	203.97	211.6	213.03	210.82
Long-Term Deferred Tax Assets	78.34	77.41	79.83	86.72	81.65
Long-Term Deferred Charges	-	0.47	1.91	3.86	2.05
Other Long-Term Assets	47.89	99.14	81.94	12.87	25.54
Total Assets	7,597	7,554	7,338	6,815	6,364
Accounts Payable	620.31	549.49	468.01	459.71	434.97
Accrued Expenses	233.37	329.92	139.77	259.48	214.52
Short-Term Debt	12.08	71.98	34.8	57.79	130
Current Portion of Long-Term Debt	-	32.63	-	-	-
Current Portion of Leases	2.04	2.64	3.34	0.3	2.72
Current Income Taxes Payable	6.28	11.71	34.67	5.61	1.18
Current Unearned Revenue	64.35	78.11	100.16	118.78	70.05
Other Current Liabilities	285.34	412.36	589.17	380.24	365.5
Total Current Liabilities	1,224	1,489	1,370	1,282	1,219
Long-Term Debt	25.79	7.7	128.5	100	-
Long-Term Leases	3.61	0.89	4.03	0.51	10.91
Long-Term Unearned Revenue	94.04	57.17	56.25	65.36	74.43
Long-Term Deferred Tax Liabilities	19.54	12.28	12.68	11.46	3.87
Total Liabilities	1,367	1,567	1,571	1,459	1,308
Common Stock	452.75	452.75	452.78	453.31	453.33
Additional Paid-In Capital	1,934	1,929	1,919	1,913	1,863
Retained Earnings	3,807	3,570	3,358	2,989	2,774
Treasury Stock	-	-	-0.08	-19.77	-32.74
Comprehensive Income & Other	-2.65	-2.71	-2.69	-2.93	-3.07
Total Common Equity	6,191	5,950	5,727	5,332	5,055
Minority Interest	39.52	37.39	39.1	23.64	0.75
Shareholders' Equity	6,231	5,987	5,766	5,356	5,056
Total Liabilities & Equity	7,597	7,554	7,338	6,815	6,364
Total Debt	43.53	115.83	170.67	158.61	143.63
Net Cash (Debt)	3,360	2,678	2,604	2,625	2,280
Net Cash Growth	25.47%	2.81%	-0.79%	15.15%	3.32%
Net Cash Per Share	7.42	5.89	5.75	5.78	5.05
Filing Date Shares Outstanding	452.75	452.75	452.76	451.36	449.83
Total Common Shares Outstanding	452.75	452.75	452.76	451.34	449.83
Working Capital	3,986	3,473	3,600	3,463	2,926
Book Value Per Share	13.67	13.14	12.65	11.81	11.24
Tangible Book Value	5,995	5,746	5,516	5,119	4,844
Tangible Book Value Per Share	13.24	12.69	12.18	11.34	10.77
Buildings	1,412	1,277	1,275	1,188	1,191
Machinery	2,469	2,109	2,092	1,903	1,797
Construction In Progress	163.6	405.8	66.68	207.17	199.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.